Gastric Cancer

P1, N=160, Recruiting, SystImmune Inc. | N=120 --> 160

P=N/A, N=60, Active, not recruiting, Ferronova Pty Ltd | Recruiting --> Active, not recruiting | Trial completion date: Feb 2029 --> May 2029 | Trial primary completion date: Feb 2026 --> May 2026

P=N/A, N=230, Not yet recruiting, First Affiliated Hospital of Zhejiang University

P=N/A, N=9, Active, not recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Recruiting --> Active, not recruiting | N=72 --> 9

This study suggests that administering chemotherapy prior to immunotherapy appears to improve OS in patients with advanced EC and GC, particularly when initiated as first-line treatment. These findings highlight the need for further research into biomarkers and personalized treatment strategies to enhance patient outcomes.

Functional assays confirmed CD18's role in monocyte migration (62.6% reduction upon blockade, p < 0.001). This exploratory study establishes an immune-based prognostic model for EBVaGC, with potential to guide risk-adapted surveillance and immunotherapy selection pending multi-center validation.

The patient completed six cycles of adjuvant chemotherapy with tegafur-gimeracil-oteracil (S-1) plus oxaliplatin, and routine follow-up examinations showed no evidence of recurrence...The patient was treated with SOX chemotherapy combined with the PD-1 inhibitor tislelizumab...This case highlights the importance of vigilance for rare metastatic sites, such as the adrenal gland, in patients with advanced gastric cancer even after standardized postoperative surveillance. Systemic chemotherapy combined with immunotherapy may represent an effective treatment strategy for selected patients with metastatic gastric cancer.

Treatment with the KXD regimen (carfilzomib, cyclophosphamide, dexamethasone) resulted in transient disease stabilization for approximately two months, followed by further progression. In addition, infiltration of CD138-positive plasma cell-like tumor cells with λ light chain restriction was observed in the gastric lamina propria, consistent with extramedullary disease (EMD). The final diagnosis was relapsed MM complicated by sPCL, gastric mucosal extramedullary plasmacytic infiltration, and synchronous moderately differentiated intramucosal papillary adenocarcinoma.

CTSK is a central hub integrating upstream signals to regulate systemic ECM homeostasis, making it a promising therapeutic target. Future therapeutic strategies should focus on developing highly selective inhibitors to achieve precise regulation and balance efficacy with safety.

Preoperative IBI and MAR are robust prognostic indicators in gastric cancer. The developed nomogram provides a practical visual tool for individualized postoperative risk assessment and management.

This review aims to summarize recent advances in understanding the molecular mechanisms underlying NSUN2 function, its clinical significance, and its potential as a biomarker or therapeutic target, while also discussing the challenges in translating these findings into clinical practice. A deeper understanding of NSUN2's diverse roles in carcinogenesis may provide novel insights into RNA epigenetics and inform the development of innovative strategies for cancer diagnosis and treatment.

We demonstrated that increased extracellular CAF-derived chemokine CCL5 leads to upregulation of GGT5 expression, alterations in EMT-related marker expression, and promotes liver metastasis in nude mice. In conclusion, targeting the CAF-derived chemokine CCL5-mediated GGT5 cascade may provide a novel therapeutic approach for GC.